MAM
ELVN icon

Meeder Asset Management’s Enliven Therapeutics ELVN Stock Holding History

Meeder Asset Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-447
Closed -$10.4K – 869
2024
Q2 		$10.4K Buy
+447
New +$9.41K ﹤0.01% 642

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Meeder Asset Management's ELVN Position: Q3 2024 in Review

Meeder Asset Management sold out of Enliven Therapeutics (ELVN) in Q3 2024, closing a stake of 447 shares — an estimated $10.4K sold.

Meeder Asset Management first reported a position in ELVN in Q2 2024 and held it in 1 quarter. The position peaked at $10.4K in Q2 2024. 102 funds tracked by Wall St. Rank hold ELVN as of Q3 2024.

  • Meeder Asset Management reported no remaining Enliven Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Meeder Asset Management sold 447 Enliven Therapeutics shares in Q3 2024, an estimated $10.4K.
  • Meeder Asset Management first reported a position in Enliven Therapeutics in Q2 2024 and held it in 1 quarter.
  • Meeder Asset Management's Enliven Therapeutics position peaked at $10.4K in Q2 2024.
  • 102 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2024.

Based on Meeder Asset Management's 13F filing for Q3 2024, filed 7 Nov 2024.